
    
      A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter
      Exacerbation Study of Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared to
      Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in COPD Patients.
    
  